Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 288 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: fulvestrant Clear all
Terminated Phase 1 Interventional

Phase I Study of the Combination of MLN9708 and Fulvestrant

NCT02384746
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, MLN9708
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Jun 7, 2026, 3:16 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Rash & Diarrhea Prophylaxis With Capivasertib

NCT07426822
View directory record Official record
Conditions
Metastatic HR+/HER2- Breast Cancer
Interventions
Capivasertib, Loperamide, Fulvestrant, Ceterizine
Drug
Lead sponsor
Maryam Lustberg
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
475
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 3 Interventional

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
52
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendale, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT07318805
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251
View directory record Official record
Conditions
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib, Abemaciclib, Carboplatin, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 2 Interventional

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285
View directory record Official record
Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions
Alisertib, Endocrine therapy
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
36
States / cities
Scottsdale, Arizona • Tucson, Arizona • Santa Rosa, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Not listed Phase 2 Interventional

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10Mg Tab
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jun 7, 2026, 3:16 AM EDT
Terminated Phase 1 Interventional

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

NCT02734615
View directory record Official record
Conditions
Advanced or Metastatic ER+ Breast Cancer
Interventions
LSZ102, LEE011, BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Jun 7, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies

NCT00417430
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ICI 182,780 (Faslodex)
Drug
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2009 · Synced Jun 7, 2026, 3:16 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

NCT02340221
View directory record Official record
Conditions
Breast Cancer
Interventions
Taselisib, Placebo, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
16
States / cities
Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jun 7, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

NCT01610284
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
61
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 2 Interventional

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

NCT05472792
View directory record Official record
Conditions
Breast Cancer, Quality of Life
Interventions
Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Completed Phase 1 Interventional

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

NCT02260661
View directory record Official record
Conditions
Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions
AZD8835, AZD8835 in combination with fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Denver, Colorado • Greenville, South Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

NCT07540572
View directory record Official record
Conditions
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
Interventions
IDE574, Fulvestrant injection
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
East Brunswick, New Jersey • Lake Success, New York • Austin, Texas + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

NCT00570323
View directory record Official record
Conditions
Breast Cancer
Interventions
Arimidex, Faslodex
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Jun 7, 2026, 3:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

NCT02345772
View directory record Official record
Conditions
HER2-positive Breast Cancer, ER-positive Breast Cancer
Interventions
fulvestrant 500 mg, Docetaxel, Trastuzumab (H, 8mg/kg, Pertuzumab (P, 840 mg
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jun 7, 2026, 3:16 AM EDT
Active, not recruiting Phase 1 Interventional

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

NCT03006172
View directory record Official record
Conditions
Breast Cancer, Solid Tumor
Interventions
Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT05608252
View directory record Official record
Conditions
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
VS-6766, Abemaciclib, Fulvestrant
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Terminated Phase 2 Interventional

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

NCT06408168
View directory record Official record
Conditions
Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Interventions
Fulvestrant, Repotrectinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Active, not recruiting Phase 4 Interventional

Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
16
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 7, 2026, 3:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

NCT02569801
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, GDC-0810
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jun 7, 2026, 3:16 AM EDT